We further showed that this approach is suitable for screening for mutations in selected genes that are associated with glomerular disorders in patients suspected to have AS or FSGS clinically, or detection of G1 or G2 APOL1 variants in African Americans. This evidence concerns the gene APOL1 and focal segmental glomerulosclerosis.